Clinical trials: Basal Cell Cancer, open to volunteers
Basal Cell Carcinoma
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
This is a phase 2 trial assessing the efficacy of nivolumab, alone or in combination with relatlimab or ipilimumab in treating patients with locally-advanced unresectable or metastatic basal cell carcinoma.
- Trial name
- NCT03521830
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Nodular BCC
Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC)
Investigational Device TSK-001 injectable glucose-functionalised gold nanoparticle solution for intratumoural administration (0.3 mg nanoparticles in 1mL water for injection) Laser device 808 nm Dose regimen TSK-001 Part 1…
- Trial name
- NCT07891949
- Testing
- TSK-001. Injectable solution of glucose-functionalised plasmonic gold nanoparticles (0.3 mg in 1 mL water for injection) for intratumoural administration., 808 nm near-infrared (NIR) diode laser (Hyper Diode 808)
- Where
- New Zealand
- Volunteers
- 78 people
- Sponsor
- Torskal SAS
Melanoma, Cutaneous Squamous Cell Carcinoma
Personalised Immunotherapy Platform
This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours.
- Conditions
- Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- PIP-PREDICT (NCT06536257)
- Testing
- Predictive model
- Where
- 3 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- Melanoma Institute Australia
Cell Carcinoma
Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp
- Trial name
- Tirbaso (NCT06112522)
- Testing
- Tirbanibulin
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
This current registry study will analyze real-world data to address questions about disease characteristics and treatment patterns in NMSC patients based on the European NMSC-Registry.
- Trial name
- NCT05741073
- Where
- Belgium
- Volunteers
- 1,300 people
- Sponsor
- EuMelaReg gGmbH
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Prostatic Neoplasms, Glioma
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
This is a study using a parallel control approach and is expected to recruit 35 volunteers, including 8 prostate cancer patients, 8 neuroendocrine tumour patients, 8 glioma patients, 8 Parkinson's syndrome patients, and 3 normal…
- Conditions
- Prostatic Neoplasms, Glioma, PARKINSON DISEASE (Disorder)
- Trial name
- NCT06914427
- Testing
- PET/CT
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Basal Cell Carcinoma of Skin, Site Unspecified, Epidermoid Carcinoma
Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis.
- Conditions
- Basal Cell Carcinoma of Skin, Site Unspecified, Epidermoid Carcinoma, Lynch Syndrome, Muir-Torre Syndrome
- Trial name
- SMT-SL (NCT07201012)
- Testing
- Sampling of suspected skin lesions (in accordance with good care practices)., Constitution of a biobank
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Head and Neck Cancer
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898638
- Testing
- biologic sample preservation procedure, medical chart review
- Where
- 4 sites in United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03889899
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Basal Cell Carcinoma
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
- Trial name
- NEON (NCT06624475)
- Testing
- Nivolumab, Relatlimab plus Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Genetic Predisposition, Paraganglioma
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic…
- Conditions
- Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS
- Trial name
- NCT06377033
- Testing
- Behavioral nudge
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Inherited Disease, Rare Diseases
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal…
- Conditions
- Inherited Disease, Rare Diseases, Metabolic Disease, Undiagnosed Disease
- Trial name
- NCT04880356
- Testing
- collection of data
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Basal Cell Carcinoma
BCC-One-Stop-Study
Basal cell carcinoma (BCC) is the most common malignant skin tumour. The standard treatment is micrographically controlled surgery (MMS), which achieves high cure rates but requires considerable time and personnel.
- Trial name
- NCT07482956
- Testing
- Margin Mapping with Line-field confocal optical coherence tomography
- Where
- 5 sites in Germany
- Volunteers
- 290 people
- Sponsor
- University Hospital Augsburg
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere